Art. -Nr.: HY-136173

Batoprotafib

(Synonyms: TNO155)

7 Cited Publications

Kundenbewertung

Based on 7 publication(s) in Google Scholar

Batoprotafib (TNO155) is a potent selective and orally active allosteric inhibitor of wild-type SHP2 (IC₅₀=0.011 µM). Batoprotafib has the potential for the study of RTK-dependent malignancies, especially advanced solid tumors.

Nur für Forschungszwecke. Wir verkaufen nicht an Patienten.

Reinheit: 99.89%
CAS. Nr.: 1801765-04-7
Formel: C₁₈H₂₄ClN₇OS
Molecular Weight:421.95

Speicherung:

Powder -20°C, 3 years , 4°C, 2 years ; In solvent -80°C, 1 year , -20°C, 6 months

Batoprotafib Chemical Structure

CAS. Nr.: 1801765-04-7

Größe

Preis

Verfügbarkeit

Menge

Amount: USD 0.00

* Bitte wählen Sie Menge, bevor Sie Artikel hinzufügen.

Top Publications Citing

Use of MCE Products

Fluorescent Dye

Strong Fluorescence Signal / Multi-Disciplinary Applications / High Fluorescence Specificity

Biologische Aktivität
- Beschreibung
- IC₅₀ & Target
- Cellular Effect
- In Vitro
- In Vivo
- Clinical Trial
Chemical Information
Publications (7)
Lösungsmittel & Löslichkeit
- In Vitro
- In Vivo
Reinheit & Dokumentation
Verweise
Help & FAQs
Classifications
Bioz

Biologische Aktivität

Beschreibung

IC₅₀ & Target

IC50: 0.011 µM (SHP2)^[1]

Cellular Effect

Cell Line	Type	Value	Description	References
EMT6	IC₅₀	2.49 μM Compound: TNO155	Antiproliferative activity against mouse EMT6 cells assessed as inhibition of cell growth incubated for 48 hrs in presence of abemaciclib by MTT assay Antiproliferative activity against mouse EMT6 cells assessed as inhibition of cell growth incubated for 48 hrs in presence of abemaciclib by MTT assay	[PMID: 35447031]
EMT6	IC₅₀	7.03 μM Compound: TNO155	Antiproliferative activity against mouse EMT6 cells assessed as inhibition of cell growth incubated for 48 hrs by MTT assay Antiproliferative activity against mouse EMT6 cells assessed as inhibition of cell growth incubated for 48 hrs by MTT assay	[PMID: 35447031]
KYSE-520 cell line	IC₅₀	0.1 μM Compound: 1, TNO155	Antiproliferative activity against human KYSE-520 cells Antiproliferative activity against human KYSE-520 cells	[PMID: 32910655]
MDA-MB-231	IC₅₀	>20 μM Compound: TNO155	Antiproliferative activity against human MDA-MB-231 cells assessed as inhibition of cell growth incubated for 48 hrs by MTT assay Antiproliferative activity against human MDA-MB-231 cells assessed as inhibition of cell growth incubated for 48 hrs by MTT assay	[PMID: 35447031]
MDA-MB-231	IC₅₀	12.94 μM Compound: TNO155	Antiproliferative activity against human MDA-MB-231 cells assessed as inhibition of cell growth incubated for 48 hrs in presence of abemaciclib by MTT assay Antiproliferative activity against human MDA-MB-231 cells assessed as inhibition of cell growth incubated for 48 hrs in presence of abemaciclib by MTT assay	[PMID: 35447031]
MDA-MB-468	IC₅₀	>20 μM Compound: TNO155	Antiproliferative activity against human MDA-MB-468 cells assessed as inhibition of cell growth incubated for 48 hrs by MTT assay Antiproliferative activity against human MDA-MB-468 cells assessed as inhibition of cell growth incubated for 48 hrs by MTT assay	[PMID: 35447031]
MDA-MB-468	IC₅₀	3.11 μM Compound: TNO155	Antiproliferative activity against human MDA-MB-468 cells assessed as inhibition of cell growth incubated for 48 hrs in presence of abemaciclib by MTT assay Antiproliferative activity against human MDA-MB-468 cells assessed as inhibition of cell growth incubated for 48 hrs in presence of abemaciclib by MTT assay	[PMID: 35447031]
MV4-11	IC₅₀	39 nM Compound: 8; TNO155	Antiproliferative activity against human MV4-11 cells assessed as inhibition of cell proliferation incubated for 72 hrs by CCK-8 assay Antiproliferative activity against human MV4-11 cells assessed as inhibition of cell proliferation incubated for 72 hrs by CCK-8 assay	[PMID: 39303516]

In Vitro

Batoprotafib shows an IC₅₀ of 0.008 μM in KYSE520 pERK assay and shows an IC₅₀ of 0.100 μM in KYSE520 5-day cell proliferation assay. The off-target IC₅₀ values are 18 μM, 6.9 μM, and 11 μM for Cav1.2, VMAT, and SST3, respectively^[1].
Batoprotafib (0-1000 nM; 6 days) inhibits the viability of NCI-H3255, HCC827, and PC9 cells with IC₅₀ values lower than 1.5 μM. Batoprotafib is efficacious in EGFR-mutant NSCLC cell lines^[2].
Batoprotafib is efficacious in acquired resistance models of EGFR inhibitors and demonstrates combination benefit with EGFR inhibitors^[2].
Batoprotafib enhances the efficacy of KRAS^G12C inhibitors against KRAS^G12C lung and colorectal cancers^[2].
Batoprotafib inhibits immune-suppressive macrophages and synergizes with PD1 blockade^[2].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

Cell Proliferation Assay^[2]

Cell Line:

PC-9, PC-9 EGFR^T790M/C797S, HCC827, HCC827-GR (gefinitib-resistant)
Concentration:

0-1000 nM
Incubation Time:

6 days
Result:

Inhibited cell viability with IC₅₀s of 1.56, 1.38, 0.77 and 1.38 μM against PC-9 and PC-9 EGFR^T790M/C797S, HCC827 and HCC827-GR cells, respectively.

Western Blot Analysis^[2]

Cell Line:

PC-14 (EGFR^ex19del)
Concentration:

3 μM
Incubation Time:

4h and 24 h
Result:

Effectively reduced p-ERK levels at 4 hours but suffered a rebound at 24 hours.

In Vivo

The oral bioavailability in mouse, rat and money are 78%, 86%, and 60%, respectively^[1].
Batoprotafib (20 mg/kg; p.o.; twice daily for 40 days) inhibits tumor growth and is more effective when combined with Dabrafenib (HY-14660) plus Trametinib (HY-10999) in nude mice bearing HT-29 xenografts^[2].
Batoprotafib (7.5 mg/kg; p.o.; b.i.d. or q.d. for 36 days) plus JDQ-443 (HY-139612) (100 mg/kg; p.o.; q.d.) improves the single-agent activity of JDQ443 in KRAS^G12C-mutated cell-derived (CDX) models in nude mice^[3].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

Animal Model:

Female athymic nude mice bearing HT-29 xenografts^[2]
Dosage:

20 mg/kg alone or 10 mg/kg in combination with Dabrafenib and Trametinib
Administration:

PO, twice daily for 40 days
Result:

Resulted in moderate tumor growth inhibition. Maintained tumor stasis for more than 40 days when combined with Dabrafenib plus Trametinib.

Clinical Trial

NCT Number	Sponsor	Condition	Start Date	Phase A549
NCT01329991	Plexxikon\|		2011-05	PHASE1

Chemical Information

CAS. Nr. 1801765-04-7
Appearance Solid
Molecular Weight 421.95
Formel C₁₈H₂₄ClN₇OS
Color Off-white to yellow
SMILES

N[C@@H]1[C@H](C)OCC12CCN(C3=NC(N)=C(SC4=C(Cl)C(N)=NC=C4)N=C3)CC2
Synonyms

TNO155
Versand

Room temperature in continental US; may vary elsewhere.

Speicherung

Powder	-20°C	3 years
	4°C	2 years
In solvent	-80°C	1 year
	-20°C	6 months

Publications (7)

All In Vivo Efficacy StudyRT-PCRCell Proliferation/Viability AssayWBFlow CytometryELISACell Migration/Invasion Assay

Sort by:

Journal Impact Factor

Cancer Cell

Anti-tumor efficacy of HRS-4642 and its potential combination with proteasome inhibition in KRAS G12D-mutant cancer. [Abstract]

2024 Jul 8;42(7):1286-1300.e8. PMID: 38942026

Batoprotafib purchased from MedChemExpress. Usage Cited in: Cancer Cell. 2024 Jul 8;42(7):1286-1300.e8. [Abstract]

Dose-response curves of inhibitor targeting SHP2 (Batoprotafib (0.1-500 nM)) (top left). Dose-response curves of HRS-4642 (bottom left), and growth inhibition matrices of indicated inhibitor combined with HRS-4642 (right) in FC1242.
Nat Commun

Mapping the landscape of genetic dependencies in chordoma. [Abstract]

2023 Apr 6;14(1):1933. PMID: 37024492

Batoprotafib purchased from MedChemExpress. Usage Cited in: Nat Commun. 2023 Apr 6;14(1):1933. [Abstract]

Tumor proliferation in mice engrafted with chordoma cells (U-CH1 cell line-derived xenograft, CF539 PDX, or CF466 PDX) and treated with a SHP2 inhibitor (RMC-4550 or Batoprotafib (TNO155) (20 mg/kg; p.o.)). Points represent the mean tumor volume ± s.e.m. (n = 4 (control) or 5 (compound) tumors for each arm of the U-CH1/RMC-4550 study; n = 6 (compound) or 7 (control) tumors for each arm of the U-CH1/TNO155 study; n = 6 (control) or 7 (compound) tumors for each arm of the CF539 study; n = 7 tumors for each arm of the CF466 study).
Eur J Cancer

HER2 mediates clinical resistance to the KRASG12C inhibitor sotorasib, which is overcome by co-targeting SHP2. [Abstract]

2021 Dec:159:16-23. PMID: 34715459
J Med Chem

2026 Feb 26;69(4):3932-3940. PMID: 41543922
Cancer Res Commun

SHP2 inhibition with TNO155 increases efficacy and overcomes resistance of ALK inhibitors in neuroblastoma. [Abstract]

2023 Dec 27;3(12):2608-2622. PMID: 38032104

Batoprotafib purchased from MedChemExpress. Usage Cited in: Cancer Res Commun. 2023 Dec 27;3(12):2608-2622. [Abstract]

Calculation of IC₅₀ in neuroblastoma cells following treatment with Batoprotafib (TNO155) for 72 hours. **, P < 0.01; ***, P < 0.001.

Batoprotafib purchased from MedChemExpress. Usage Cited in: Cancer Res Commun. 2023 Dec 27;3(12):2608-2622. [Abstract]

Western immunoblots of Kelly and SH-SY5Y cells treated with Batoprotafib (TNO155) (1 µmol/L), lorlatinib (1 µmol/L), or combination for 24 hours. Batoprotafib (TNO155) plus lorlatinib treatment showed marked inhibition of ALK and SHP2 activity, including inactivation of MAPK downstream signaling.
Int J Biochem Cell Biol

MEST promotes immune escape in gastric cancer by downregulating MHCI expression via SHP2. [Abstract]

2024 Sep:174:106621. PMID: 39181599

Batoprotafib purchased from MedChemExpress. Usage Cited in: Int J Biochem Cell Biol. 2024 Sep:174:106621. [Abstract]

Co-culture of three different groups of GC cells (oe-NC+DMSO, oe-NC+TNO155 (Batoprotafib) (1 μM; 24 h), oe-MEST+TNO155) with CD8⁺ T cells; qPCR detection of the expression of MHCI-related genes and SHP2 in GC cells. The results showed that TNO155 significantly promoted the expression of MCHI-related genes, and oe-MEST+TNO155 partially reversed the increase in MCHI-related gene expression.

Batoprotafib purchased from MedChemExpress. Usage Cited in: Int J Biochem Cell Biol. 2024 Sep:174:106621. [Abstract]

Co-culture of three different groups of GC cells (oe-NC+DMSO, oe-NC+TNO155 (Batoprotafib) (1 μM; 24 h), oe-MEST+TNO155) with CD8⁺ T cells; WB detection of the expression of MHCI-related genes and SHP2 in GC cells. The results showed that TNO155 significantly inhibited SHP2 expression, and oe-MEST+TNO155 restored SHP2 expression to the control group level.

Batoprotafib purchased from MedChemExpress. Usage Cited in: Int J Biochem Cell Biol. 2024 Sep:174:106621. [Abstract]

LDH assay of cytotoxicity of CD8+ T cells. The results showed that TNO155 (Batoprotafib) (1 μM; 24 h) significantly enhanced the killing of HGC-27 cells by CD8⁺ T cells, and further overexpression of MEST attenuated the increased cytotoxicity of CD8⁺ T cells.

Batoprotafib purchased from MedChemExpress. Usage Cited in: Int J Biochem Cell Biol. 2024 Sep:174:106621. [Abstract]

Flow cytometry analysis of cellular apoptosis. The results showed that compared to the control group, TNO155 (Batoprotafib) (1 μM; 24 h) significantly increased the apoptotic rate of HGC-27 cells, while further overexpression of MEST significantly reduced the apoptotic rate of HGC-27 cells.

Batoprotafib purchased from MedChemExpress. Usage Cited in: Int J Biochem Cell Biol. 2024 Sep:174:106621. [Abstract]

ELISA measurement of concentration of IFN-γ in cell culture supernatant. ELISA results indicated that compared to the control group, TNO155 (Batoprotafib) (1 μM; 24 h) significantly increased the levels of IFN-γ and TNF-α in the supernatant of HGC-27 cells, while after overexpression of MEST, the levels of IFN-γ and TNF-α in the supernatant were significantly reduced.

Batoprotafib purchased from MedChemExpress. Usage Cited in: Int J Biochem Cell Biol. 2024 Sep:174:106621. [Abstract]

Transwell measurement of the migration of GC cells after co-culturing with CD8⁺ T cells. Transwell assays revealed that the migration and invasion abilities of HGC-27 cells were significantly reduced upon the addition of TNO155 (Batoprotafib) (1 μM; 24 h), while in the oe-MEST+TNO155, the migration and invasion abilities of the tumor cells were restored to the control group level.
bioRxiv

2026 Jun 25.

Lösungsmittel & Löslichkeit

In Vitro:

DMSO : 66.67 mg/mL (158.00 mM; Need ultrasonic; Hygroscopic DMSO has a significant impact on the solubility of product, please use newly opened DMSO)

View the Complete Stock Solution Preparation Table

Preparing Stock Solutions

View the Complete Stock Solution Preparation Table

Concentration Solvent Mass

1 mg

5 mg

10 mg

Concentration

Solvent

Mass

1 mM

2.3699 mL

11.8497 mL

23.6995 mL

5 mM

0.4740 mL

2.3699 mL

4.7399 mL

10 mM

0.2370 mL

1.1850 mL

2.3699 mL

Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.

Storage method and period of stock solution: -80°C, 1 year; -20°C, 6 months. When stored at -80°C, please use it within 1 year. When stored at -20°C, please use it within 6 months.

Molaritätsrechner

Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)

Mass Mass

Konzentration Konzentration

Volumen Volumen

Molecular Weight Molecular Weight

Verdünnungsrechner

Konzentration _{(Stammlösung)} × Volumen _{(Stammlösung)} = Konzentration _{(Ziellösung)} × Volumen _{(Ziellösung)}

Konzentration _{(Stammlösung)} Konzentration _{(Stammlösung)}

Volumen _{(Stammlösung)} Volumen _{(Stammlösung)}

Konzentration _{(Ziellösung)} Konzentration _{(Ziellösung)}

Volumen _{(Ziellösung)} Volumen _{(Ziellösung)}

In Vivo:

Select the appropriate dissolution method based on your experimental animal and administration route.

Stock Solution Working Solution

For the following dissolution methods, please ensure to first prepare a clear stock solution using an In Vitro approach and then sequentially add co-solvents:
To ensure reliable experimental results, the clarified stock solution can be appropriately stored based on storage conditions. As for the working solution for In Vivo experiments, it is recommended to prepare freshly and use it on the same day.
The percentages shown for the solvents indicate their volumetric ratio in the final prepared solution. If precipitation or phase separation occurs during preparation, heat and/or sonication can be used to aid dissolution.

Protocol 1

Add each solvent one by one: 10% DMSO 40% PEG300 5% Tween-80 45% Saline

Solubility: ≥ 2.5 mg/mL (5.92 mM); Clear solution

This protocol yields a clear solution of ≥ 2.5 mg/mL (saturation unknown).

Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (25.0 mg/mL) to 400 μL PEG300, and mix evenly; then add 50 μL Tween-80 and mix evenly; then add 450 μL Saline to adjust the volume to 1 mL.

Protocol 2

Add each solvent one by one: 10% DMSO 90% (20% SBE-β-CD in Saline)

Solubility: ≥ 2.5 mg/mL (5.92 mM); Clear solution

This protocol yields a clear solution of ≥ 2.5 mg/mL (saturation unknown).

Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (25.0 mg/mL) to 900 μL 20% SBE-β-CD in Saline, and mix evenly.

Protocol 3

Add each solvent one by one: 5% DMSO 40% PEG300 5% Tween-80 50% Saline

Solubility: ≥ 2.5 mg/mL (5.92 mM); Clear solution

Protocol 4

Add each solvent one by one: 10% DMSO 90% Corn Oil

Solubility: ≥ 2.08 mg/mL (4.93 mM); Clear solution

This protocol yields a clear solution of ≥ 2.08 mg/mL (saturation unknown). If the continuous dosing period exceeds half a month, please choose this protocol carefully.

Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (20.8 mg/mL) to 900 μL Corn oil, and mix evenly.

In Vivo Dissolution Calculator

Please enter the basic information of animal experiments:

Dosage Dosage
mg/kg
Animal Weight (Per Animal) Animal Weight (Per Animal)
g
Dosing Volume (Per Animal) Dosing Volume (Per Animal)
μL
Number of Animals Number of Animals

Recommended: Prepare an additional quantity of animals to account for potential losses during experiments.

Recommended: Prepare an additional quantity of animals to account for potential losses during experiments.

Please enter your animal formula composition:

%
DMSO +

Recommended: Keep the proportion of DMSO in working solution below 2% if your animal is weak.
%
+
+
%
Tween-80 + +
%
Saline +

The co-solvents required include: DMSO, . All of co-solvents are available by MedChemExpress (MCE). , Tween 80. All of co-solvents are available by MedChemExpress (MCE).

Working solution concentration: 0.22 mg/mL

Reinheit & Dokumentation

Select Batch:

Reinheit: 99.98%

Assay: 99.98%

ee.: 99.98%

Data Sheet (280 KB)
SDS (393 KB)
- English - EN (393 KB)
- Français - FR (393 KB)
- Deutsch - DE (393 KB)
- Norwegian - NO (393 KB)
- Español - ES (393 KB)
- Swedish - SV (393 KB)
- Italian - IT (393 KB)
- Korean - KR (393 KB)
- Portuguese - PT (393 KB)
COA (2659 KB)
Elemental Analysis Report (2659 KB)
HNMR (2659 KB)
CNMR (2659 KB)
RP-HPLC (2659 KB)
NP-HPLC (2659 KB)
MS (2659 KB)
LCMS (2659 KB)
IR (2659 KB)
GC (2659 KB)
OR (2659 KB)
SDS-PAGE (2659 KB)
SEC-HPLC (2659 KB)
Other Report (2659 KB)
Handling Instructions (2659 KB)

Verweise

[1]. TNO155: SHP2 inhibitor

[2]. Liu C, et al. Combinations with Allosteric SHP2 Inhibitor TNO155 to Block Receptor Tyrosine Kinase Signaling. Clin Cancer Res. 2021 Jan 1;27(1):342-354. [Content Brief]

[3]. Weiss A, et al. Discovery, Preclinical Characterization, and Early Clinical Activity of JDQ443, a Structurally Novel, Potent, and Selective Covalent Oral Inhibitor of KRASG12C. Cancer Discov. 2022 Jun 2;12(6):1500-1517. [Content Brief]

Help & FAQs

How should lyophilized recombinant proteins be reconstituted and stored?

1. Before opening the cap, centrifuge the vial at 13000 rpm for 20-30 seconds. This step will ensure that any lyophilized powder that may have adhered to the cap or walls is collected at the bottom of the vial, minimizing the risk of product loss.

Complete Stock Solution Preparation Table

Storage method and period of stock solution: -80°C, 1 year; -20°C, 6 months. When stored at -80°C, please use it within 1 year. When stored at -20°C, please use it within 6 months.

Optional Solvent	Concentration Solvent Mass	1 mg	5 mg	10 mg	25 mg
DMSO	1 mM	2.3699 mL	11.8497 mL	23.6995 mL	59.2487 mL
	5 mM	0.4740 mL	2.3699 mL	4.7399 mL	11.8497 mL
	10 mM	0.2370 mL	1.1850 mL	2.3699 mL	5.9249 mL
	15 mM	0.1580 mL	0.7900 mL	1.5800 mL	3.9499 mL
	20 mM	0.1185 mL	0.5925 mL	1.1850 mL	2.9624 mL
	25 mM	0.0948 mL	0.4740 mL	0.9480 mL	2.3699 mL
	30 mM	0.0790 mL	0.3950 mL	0.7900 mL	1.9750 mL
	40 mM	0.0592 mL	0.2962 mL	0.5925 mL	1.4812 mL
	50 mM	0.0474 mL	0.2370 mL	0.4740 mL	1.1850 mL
	60 mM	0.0395 mL	0.1975 mL	0.3950 mL	0.9875 mL
	80 mM	0.0296 mL	0.1481 mL	0.2962 mL	0.7406 mL
	100 mM	0.0237 mL	0.1185 mL	0.2370 mL	0.5925 mL

Batoprotafib

7 Cited Publications

100 mg Angebot einholen

Subscribe to the

MedChemExpress

Newsletter

Produktname:
Art. -Nr.:
Menge:
MCE Japan Authorized Agent:

Produktname:
CAS. Nr.:
Species:
Reinheit:
Menge:

Batoprotafib

Kinase Inhibitor Library

Metabolism/Protease Compound Library

Protein Tyrosine Kinase Compound Library

Anti-Cancer Compound Library

Clinical Compound Library

Drug Repurposing Compound Library

Anti-Lung Cancer Compound Library

Anti-Pancreatic Cancer Compound Library

Phosphatase Inhibitor Library

Anti-Prostate Cancer Compound Library

Heterocyclic Compound Library

Metabolic Enzyme Compound Library

Highly Selective Inhibitors Library

Multi-Target Compound Library

Bioactive Compound Library Max

MCE Bioactive Compound Library

Drug Repurposing Compound Library Plus

Clinical Compound Library Plus

Bioactive Compound Library

Protein Kinase Compound Library

High-Throughput Bioactive Compound Library

Posttranslational Modification Library

Publications Citing Use of MedChemExpress (MCE) Batoprotafib

Biologische Aktivität

Chemical Information

Publications (7)

Lösungsmittel & Löslichkeit

Reinheit & Dokumentation

Verweise

Help & FAQs

Complete Stock Solution Preparation Table

Batoprotafib

Kinase Inhibitor Library

Metabolism/Protease Compound Library

Protein Tyrosine Kinase Compound Library

Anti-Cancer Compound Library

Clinical Compound Library

Drug Repurposing Compound Library

Anti-Lung Cancer Compound Library

Anti-Pancreatic Cancer Compound Library

Phosphatase Inhibitor Library

Anti-Prostate Cancer Compound Library

Heterocyclic Compound Library

Metabolic Enzyme Compound Library

Highly Selective Inhibitors Library

Multi-Target Compound Library

Bioactive Compound Library Max

MCE Bioactive Compound Library

Drug Repurposing Compound Library Plus

Clinical Compound Library Plus

Bioactive Compound Library

Protein Kinase Compound Library

High-Throughput Bioactive Compound Library

Posttranslational Modification Library

Publications Citing Use of MedChemExpress (MCE) Batoprotafib

Biologische Aktivität

Chemical Information

Publications (7)

Lösungsmittel & Löslichkeit

Reinheit & Dokumentation

Verweise

Help & FAQs

Complete Stock Solution Preparation Table

Batoprotafib Related Classifications

HY-136173 Related Classifications